“…They expose death ligands, which may kill attacking immune effector cells (reviewed by Igney and Krammer, 2005), they downregulate the expression of death receptors (Bachmann et al, 2001) and/or upregulate molecules that interfere with apoptotic pathways (Trisciuoglio et al, 2005). BCCs highly express Fas ligand, but not the corresponding receptor Fas (Buechner et al, 1997). This may make the tumor resistant to the attack of Fas-positive immune effector cells .…”